PP
LRMR icon

PDT Partners’s Larimar Therapeutics LRMR Stock Holding History

PDT Partners’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,633
Closed -$54K – 438
2019
Q1 		$54K Sell
1,633
-185
-10% -$9.48K ﹤0.01% 424
2018
Q4 		$108K Buy
1,818
+507
+39% +$50K 0.01% 441
2018
Q3 		$184K Sell
1,311
-324
-20% -$39.3K 0.01% 437
2018
Q2 		$201K Sell
1,635
-1,301
-44% -$111K 0.01% 470
2018
Q1 		$262K Buy
2,936
+469
+19% +$39.8K 0.01% 500
2017
Q4 		$137K Sell
2,467
-2,675
-52% -$121K ﹤0.01% 518
2017
Q3 		$217K Sell
5,142
-1,075
-17% -$44.7K 0.01% 489
2017
Q2 		$262K Hold
6,217
– – 0.01% 464
2017
Q1 		$348K Buy
+6,217
New +$309K 0.02% 412

Other funds holding LRMR

AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PDT Partners's LRMR Position: Q2 2019 in Review

PDT Partners sold out of Larimar Therapeutics (LRMR) in Q2 2019, closing a stake of 1,633 shares — an estimated $54K sold.

PDT Partners first reported a position in LRMR in Q1 2017 and held it in 9 quarters. The position peaked at $348K in Q1 2017. 71 funds tracked by Wall St. Rank hold LRMR as of Q2 2019.

  • PDT Partners reported no remaining Larimar Therapeutics position as of Q2 2019 after selling out during the quarter.
  • PDT Partners sold 1,633 Larimar Therapeutics shares in Q2 2019, an estimated $54K.
  • PDT Partners first reported a position in Larimar Therapeutics in Q1 2017 and held it in 9 quarters.
  • PDT Partners's Larimar Therapeutics position peaked at $348K in Q1 2017.
  • 71 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2019.

Based on PDT Partners's 13F filing for Q2 2019, filed 14 Aug 2019.